TTrialPathMatch Me to Trials
← Back to trials
RecruitingAntiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)Behçet's Syndrome (BS)

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Eligible age

18–85 yrs

Accepts

All genders

Locations

8 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).

Sponsor: Chugai Pharmaceutical

You may not qualify if…

  • ✕ 1. History of anaphylaxis or hypersensitivity to a biologic agent
  • ✕ 2. Active infection requiring systemic antiviral, antibiotics or antifungal
  • ✕ 3. Planned surgery during the study
  • ✕ 4. Pregnant or breastfeeding, or intending to become pregnant
  • ✕ 5. Any serious medical condition or abnormality in clinical laboratory tests that precludes the patient's safe participation in and completion of the study
  • ✕ 6. Clinically significant ECG abnormalities
  • ✕ 7. Illicit drug or alcohol abuse
  • ✕ 8. Clinical diagnosis of autoimmune diseases other than the target disease (except for Sjögren's syndrome in DM and IMNM)

Where it's recruiting

Maryland

Baltimore

New York

Lake Success · New York

North Carolina

Chapel Hill

Ohio

Columbus

Oregon

Portland

Pennsylvania

Philadelphia

Texas

Amarillo · Austin · Houston

Source: ClinicalTrials.gov · NCT06371417 · last updated 2026-07-22

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) · TrialPath